On March 6, 2019 LIDDS AB reported that the last patient has been enrolled in LIDDS Phase IIb study for the localized treatment of prostate cancer (Press release, Lidds, MAR 6, 2019, View Source [SID1234555910]). The Phase IIb study will identify the optimal dose for Phase III and test the safety of Liproca Depot and its effectiveness in stopping cancer progression. Liproca Depot is based on LIDDS unique NanoZolid drug delivery technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

-We are very pleased that patient recruitment is now finalized and we look forward to concluding the study and receiving the results in third quarter this year, says Monica Wallter, CEO.

-We expect this study to show that by injecting Liproca Depot directly into the tumor, prostate cancer progression can be stopped and patients can avoid radical surgery and radiation therapy which are associated with side effects such as sexual dysfunction and incontinence, says Monica Wallter.

-A large prostate cancer patient group is currently not receiving any treatment and Liproca Depot has the potential to provide a new treatment regimen that will benefit healthcare providers and prostate cancer sufferers in a market worth over USD 9 billion annually, says Monica Wallter.

The Phase IIb study for Liproca Depot includes 60 patients and is being conducted at major urology clinics in Canada, Finland and Lithuania.

LIDDS has already signed an exclusive licensing agreement for Liproca Depot in China with the Puheng Jiangxi pharmaceutical company. Preparations are ongoing in China for a Phase III clinical study that will be fully funded by the Chinese licensee. Prostate cancer is a very common disease in China and around 500 000 patients are diagnosed each year.

-We look forward to continuing our dialogue with major pharmaceutical companies on out-licensing Liproca Depot in the US, Europe and the rest of the world. With more than USD 3 billion currently being spent each year on localized prostate cancer treatment, Liproca Depot can offer a new regimen that benefits patients, healthcare providers and pharmaceutical companies, says Monica Wallter.

About the study:
The study (LPC-004) consists of two parts. The first part of the study is evaluating the tolerability and safety of substantially higher doses of the anti-androgen 2-HOF (2-hydroxyflutamide) compared to earlier Phase II studies with Liproca Depot. In the second part, consisting of 40 patients, LIDDS will receive efficacy results measured with the biomarker PSA, prostate volume, MRI data and Quality of Life reports.

In the study, patients diagnosed with a localized non-aggressive prostate cancer received intra-prostatic injections of Liproca Depot containing NanoZolid and the anti-androgen drug 2-HOF. All participating subjects were defined as "Active Surveillance" patients, not chosen for surgery or radiation therapy. Patients are being followed for six months to assess the anti-androgen response and cancer control.

On March 6, 2019 Ophthotech Corporation (Nasdaq: OPHT) reported that Kourous A. Rezaei, M.D., Chief Medical Officer of Ophthotech, will present an overview of the Company at the Cowen and Company 39th Annual Health Care Conference in Boston, MA, on Wednesday, March 13, 2019 at 9:20 a.m. Eastern Time (Press release, Ophthotech, MAR 6, 2019, https://investors.ophthotech.com/news-releases/news-release-details/ophthotech-present-cowen-and-company-39th-annual-health-care [SID1234534011]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations section on the Ophthotech website at www.ophthotech.com. An archived replay of the webcast will be available on the website for 14 days after the conference.

On March 6, 2019 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to make the following presentations later this month (Press release, CRISPR Therapeutics, MAR 6, 2019, View Source [SID1234534027]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Barclays Global Healthcare Conference
Date: Wednesday, March 13, 2019
Presentation: 10:15 a.m. ET
Location: Miami, FL

Oppenheimer’s 29th Annual Healthcare Conference
Date: Wednesday, March 20, 2019
Presentation: 1:35 p.m. ET
Location: New York, NY

A live webcast of the events will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcasts will be archived on the Company’s website for 14 days following each presentation.

On March 6, 2019 Bristol-Myers Squibb Company (NYSE:BMY) reported that it will take part in a fireside chat at the Barclays 2019 Global Healthcare Conference on Wednesday, March 13, 2019, in Miami (Press release, Bristol-Myers Squibb, MAR 6, 2019, View Source [SID1234534047]). Charles Bancroft, executive vice president, Chief Financial Officer and Head of Global Business Operations, will answer questions at 12:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

On March 6, 2019 CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, reported the pricing of its previously announced underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $12.50 per share, before underwriting discounts and commissions (Press release, CymaBay Therapeutics, MAR 6, 2019, View Source [SID1234534028]). All of the shares of common stock are being offered by CymaBay. In addition, CymaBay has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price less underwriting discounts and commissions. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering is expected to close on March 8, 2019, subject to the satisfaction of customary closing conditions.

Citigroup, Evercore ISI and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners are acting as co-managers for the offering.

The securities described above are being offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement and the accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or telephone: 1-800-831-9146; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, or by telephone at (888) 474-0200, or by email at [email protected]; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.